Mpox Surveillance Based on Rash Characteristics - 13 Emergency Departments, United States, June-December 2023
- PMID: 38843078
- PMCID: PMC11166258
- DOI: 10.15585/mmwr.mm7322a1
Mpox Surveillance Based on Rash Characteristics - 13 Emergency Departments, United States, June-December 2023
Abstract
In 2022, a global mpox outbreak occurred, primarily affecting gay and bisexual men who have sex with men (GBMSM). To screen for mpox's reemergence and investigate potentially unsuspected cases among non-GBMSM, prospective surveillance of patients aged ≥3 months with an mpox-compatible rash (vesicular, pustular, ulcerated, or crusted) was conducted at 13 U.S. emergency departments (EDs) during June-December 2023. Demographic, historical, and illness characteristics were collected using questionnaires and electronic health records. Lesions were tested for monkeypox virus using polymerase chain reaction. Among 196 enrolled persons, the median age was 37.5 years (IQR = 21.0-53.5 years); 39 (19.9%) were aged <16 years, and 108 (55.1%) were male. Among all enrollees, 13 (6.6%) were GBMSM. Overall, approximately one half (46.4%) and one quarter (23.5%) of enrolled persons were non-Hispanic White and non-Hispanic Black or African American, respectively, and 38.8% reported Hispanic or Latino (Hispanic) ethnicity. Unstable housing was reported by 21 (10.7%) enrollees, and 24 (12.2%) lacked health insurance. The prevalence of mpox among ED patients evaluated for an mpox-compatible rash was 1.5% (95% CI = 0.3%-4.4%); all persons with a confirmed mpox diagnosis identified as GBMSM and reported being HIV-negative, not being vaccinated against mpox, and having engaged in sex with one or more partners met through smartphone dating applications. No cases were identified among women, children, or unhoused persons. Clinicians should remain vigilant for mpox and educate persons at risk for mpox about modifying behaviors that increase risk and the importance of receiving 2 appropriately spaced doses of JYNNEOS vaccine to prevent mpox.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Kavitha Pathmarajah reports institutional support from the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Carl T. Berdahl reports institutional support from the Emergency Medicine Foundation, Gordon and Betty Moore Foundation, Society to Improve Diagnosis in Medicine, and VisualDx, and receipt of consulting fees from INFOTECHSoft, Inc. Gregory J. Moran reports institutional support from AbVacc, receipt of consulting fees from Light AI and Hippo Education, and stock options in Light AI. Matthew Waxman reports provision of expert consultation in medical malpractice cases in the past and unpaid membership on the Refugee Health Alliance board and the Drugs and Diagnostics for Tropical Diseases board. William Mower reports institutional support from NIH, receipt of payment for medicolegal consulting with numerous firms, and shares of common stock in Medtronics, Johnson & Johnson, and Pfizer. David A. Talan reports institutional support from NIAID and the Antibacterial Resistance Leadership Group, consulting fees from bioMerieux, Inc. and GSK, honoraria from New York University and Vanderbilt University, and stock options in Light AI. Sam S. Torbati reports payment for expert testimony from Ikuta Hemesath, LLP and Mokri Vanis & Jones, LLP and unpaid membership on the Los Angeles Region Chapter of the American Red Cross board. Omai B. Garner reports institutional support from National Science Foundation, bioMerieux, Inc., Beckman Coulter, and Diasorin, receipt of consulting fees from Seegene Diagnostics, and lecture honorarium from Roche Diagnostics. No other potential conflicts of interest were disclosed.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
